Andrea Bor1, Mária Matuz2, Nóra Gyimesi2, Zsuzsanna Biczók2, Gyöngyvér Soós2, Péter Doró2. 1. University of Szeged, Faculty of Pharmacy, Department of Clinical Pharmacy, Szikra utca 8, 6725 Szeged, Hungary. Electronic address: andrea.bor@pharm.u-szeged.hu. 2. University of Szeged, Faculty of Pharmacy, Department of Clinical Pharmacy, Szikra utca 8, 6725 Szeged, Hungary.
Abstract
INTRODUCTION: Our aim was to perform both gender- and age-specific analysis regarding the utilisation of anti-osteoporotic drugs in Hungary, between 2007 and 2011, and to compare our results with other European countries. METHODS: The database of the Hungarian National Health Insurance Fund was screened for anti-osteoporotic medications, covering 100% of the Hungarian population (10 million people). ICD coding system (International Classification of Diseases) and WHO ATC/DDD methodology were used for medication screening and analysis. RESULTS: In Hungary, the total bisphosphonate use was 6.66 DDD/TID (Defined Daily Dose/1000 inhabitants/day) in 2007, and 6.22 DDD/TID in 2011; the rate of bisphosphonate combinations slightly increased from 1.60 to 2.81 DDD/TID. The total vitamin D use almost doubled (13.73 DDD/TID in 2011), while the calcium supplementation tripled (4.47 DDD/TID in 2011), and so did the strontium ranelate utilisation (0.70 DDD/TID in 2011) within the investigated time period. Denosumab consumption was marginal. Male patients were disproportionately, 10-20 times undertreated in all age groups, and treatment choice was restricted among men. Several differences were seen in our results compared to those in Baltic countries, Finland and in Norway. CONCLUSIONS: Men were significantly undertreated in all age groups, compared to women. The 10 to 20-fold difference calls attention to this unrecognised problem.
INTRODUCTION: Our aim was to perform both gender- and age-specific analysis regarding the utilisation of anti-osteoporotic drugs in Hungary, between 2007 and 2011, and to compare our results with other European countries. METHODS: The database of the Hungarian National Health Insurance Fund was screened for anti-osteoporotic medications, covering 100% of the Hungarian population (10 million people). ICD coding system (International Classification of Diseases) and WHO ATC/DDD methodology were used for medication screening and analysis. RESULTS: In Hungary, the total bisphosphonate use was 6.66 DDD/TID (Defined Daily Dose/1000 inhabitants/day) in 2007, and 6.22 DDD/TID in 2011; the rate of bisphosphonate combinations slightly increased from 1.60 to 2.81 DDD/TID. The total vitamin D use almost doubled (13.73 DDD/TID in 2011), while the calcium supplementation tripled (4.47 DDD/TID in 2011), and so did the strontium ranelate utilisation (0.70 DDD/TID in 2011) within the investigated time period. Denosumab consumption was marginal. Male patients were disproportionately, 10-20 times undertreated in all age groups, and treatment choice was restricted among men. Several differences were seen in our results compared to those in Baltic countries, Finland and in Norway. CONCLUSIONS:Men were significantly undertreated in all age groups, compared to women. The 10 to 20-fold difference calls attention to this unrecognised problem.
Authors: Andrea Bor; Mária Matuz; Márta Csatordai; Gábor Szalai; András Bálint; Ria Benkő; Gyöngyvér Soós; Péter Doró Journal: Int J Clin Pharm Date: 2017-02-10
Authors: A Pereira da Silva; A Matos; A Valente; Â Gil; I Alonso; R Ribeiro; M Bicho; J Gorjão-Clara Journal: J Nutr Health Aging Date: 2016-03 Impact factor: 4.075
Authors: Alan M Rathbun; Michelle Shardell; Denise Orwig; J Richard Hebel; Gregory E Hicks; Thomas J Beck; Jay Magaziner; Marc C Hochberg Journal: Bone Date: 2016-08-26 Impact factor: 4.398
Authors: Alan M Rathbun; Michelle Shardell; Denise Orwig; J Richard Hebel; Gregory E Hicks; Thomas Beck; Marc C Hochberg; Jay Magaziner Journal: Arch Osteoporos Date: 2016-02-04 Impact factor: 2.617